Addiction, Author Interviews, COVID -19 Coronavirus, Opiods / 07.02.2023
Geisinger Study: Methadone ‘take-homes’ during COVID-19 Resulted in Greater Methadone Overdoses
MedicalResearch.com Interview with:
Brian Piper, PhD MS
Assistant Professor of Neuroscience
Center for Pharmacy Innovation & Outcomes
Geisinger School of Graduate Education
MedicalResearch.com: What is the background for this study?
Response: Methadone is an evidence-based treatment of opioid use disorder (OUD) and pain. However, this Schedule II opioid can also cause respiratory depression, which can result in lethality. The need for supervised administration is a long-standing source of frustration in the U.S. for many opioid use disorder (OUD) methadone patients. However, there was an accommodation in early 2020 thanks to the COVID-19 pandemic. This involved extending the take-home supply to up to 28-days for stable patients and 14 days for less stable patients. Prior research found that the implementation of supervised administration in England greatly reduced methadone overdoses [1]. The primary objective of this study [2] from Geisinger Commonwealth School of Medicine was to determine if the relaxation of the take-home rules resulted in more methadone overdoses. (more…)